Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells

Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in the world. Neoadjuvant chemotherapy (NAC) has become a standard treatment for patients scheduled for surgical resection, but the high rate of postoperative recurrence is a critical problem. Optimization of NAC is desirable to...

Full description

Saved in:
Bibliographic Details
Main Authors: Keisuke Takemura, Kyohei Ikeda, Hayato Miyake, Yoshio Sogame, Hiroaki Yasuda, Nobuhiro Okada, Kazumi Iwata, Junichi Sakagami, Kanji Yamaguchi, Yoshito Itoh, Atsushi Umemura
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Biomolecules
Subjects:
pancreatic ductal adenocarcinoma
neoadjuvant chemotherapy
epithelial–mesenchymal transition
ML210
gemcitabine
Online Access:https://www.mdpi.com/2218-273X/15/1/70
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items